Danazol: An Effective and Underutilised Treatment Option in Diamond-Blackfan Anaemia

Kern Y. Chai, Cara J. Quijano, Shingirai Chiruka
In: Case Reports in Hematology · 2019 · vol. 2019 , pp. 1–5 · doi:10.1155/2019/4684156 · PMID:31355022 · W2955836464
article OA: gold CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

Diamond-Blackfan anaemia (DBA) is a rare congenital red cell aplasia that presents in infancy. The exact molecular mechanism of ineffective erythropoiesis and red cell aplasia remains unclear, rendering targeted therapy elusive. The mainstay treatment of DBA is with regular blood transfusion and long-term corticosteroids, both of which have long-term side effects. We report a case of DBA successfully treated with danazol, a synthetic androgen, and suggest that danazol be considered as a viable option in patients who become refractory to steroids and are considered high risk or unfit for allogeneic stem cell transplantation.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-14T06:45:28.448396+00:00
License: CC0 · commercial use OK